Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

F029 - Practical Approaches to Assessing Psoriasis and Psoriatic Arthritis Patients in Clinic

Friday, February 16; 1:00 PM - 3:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Recognize the importance of assessing patients for psoriasis, psoriatic arthritis.
  • Select tools and scales for the clinical assessment of disease severity and quality of life in patients with psoriasis, psoriatic arthritis for routine clinical use.
  • Use clinical assessment results to select appropriate treatment regimen with the goal of treating to target for patients with psoriasis and/or psoriatic arthritis for better patient outcomes.

Description

The session will be helpful in expanding physician knowledge base and improving clinical confidence and effectiveness in assessing disease severity and quality of life tools in treating patients with psoriasis and psoriatic arthritis. The session will consist of five didactic presentations, interactive patient assessment demonstrations, and virtual patient assessment experiences. Participants will receive implementation tools consisting of laminated pocket cards, reference booklets, score cards, checklists, and apps, as deemed appropriate by expert psoriasis and PsA faculty to ensure practicality in aiding participants in improving their clinical practice (while supplies last). This activity has been approved by the American Board of Dermatology (ABD) for up to 20 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org

Disclosures

  • Callis-Duffin, Kristina Patrice, MD: AbbVie – C(H), I(Grants/Research Funding), SP(H); Amgen – A(H), C(H), I(Grants/Research Funding); Bristol-Myers Squibb – C(Fees); Celgene Corporation – A(H), I(Grants/Research Funding); Eli Lilly and Company – C(H), I(Grants/Research Funding); Janssen Pharmaceuticals, Inc – A(H), I(Grants/Research Funding); Novartis – C(H), I(Grants/Research Funding); Pfizer Inc. – C(H), I(Grants/Research Funding); Sienna Biopharmaceuticals – C(H), I(Grants/Research Funding); Stiefel a GSK company – I(Grants/Research Funding); Xenoport, Inc – I(Grants/Research Funding);
  • Gelfand, Joel M., MD, MSCE: AbbVie – I(Grants/Research Funding); American Academy of Dermatology – SP(H); Celgene Corporation – I(Grants/Research Funding); Coherus Biosciences – Data Safety Monitoring Board(H); Dermira – C(H); Dr. Reddy – C(H); Eli Lilly and Company – I(Grants/Research Funding); Elsevier Inc. – O(NC); Janssen Pharmaceuticals, Inc – C(H), I(Grants/Research Funding); Menlo Therapeutics – C(H); Merck & Co., Inc – Data Safety Monitoring Board(H); Novartis Pharmaceuticals Corp. – C(H), I(Grants/Research Funding); Pfizer Inc. – C(H), I(Grants/Research Funding); Regeneron – C(H), I(Grants/Research Funding); Sanofi – I(Grants/Research Funding); Sanofi US Services – A(H); Society for Investigative Dermatology – O(NC);
  • Merola, Joseph, MD, MSc: AbbVie – A(H), SP(H); Amgen – A(H), I(NC); Biogen – C(Fees), I(Grants/Research Funding); Eli Lilly and Company – A(Grants/Research Funding); Janssen Pharmaceuticals, Inc – A(H); Momenta Pharmaceuticals, Inc. – C(H); Novartis – A(H); Pfizer Inc. – I(NC);
  • Strober, Bruce Elliot, MD, PhD: AbbVie – A(H), C(H), I(NC), O(NC); Almirall – C(H); Amgen – C(H), I(NC); Boehringer Ingelheim – C(H), I(NC); Celgene Corporation – A(H), C(H), I(NC); Dermira – A(H), C(H); Eli Lilly and Company – A(H), C(H), I(NC); Janssen-Ortho Inc. – A(H), C(H), I(NC), O(NC); Leo Pharma Inc – C(H); Merck & Co., Inc – I(NC); Novartis Pharmaceuticals Corp. – A(H), C(H); Pfizer Inc. – A(H), C(H), I(NC); Sanofi/Regeneron – A(H), C(H); Sun Pharmaceutical Industries Ltd. – A(H), C(H), I(NC); UCB – A(H), C(Fees);
  • Takeshita, Junko, MD, PhD: Pfizer Inc. – I(Grants/Research Funding);
Schedule
Friday, February 16
1:00 PM
Dr. Gelfand / Introduction
1:05 PM
Dr. Callis-Duffin / Patient assessment demonstration and clinical use of assessment tools for psoriasis
1:45 PM
Dr. Merola / Patient Assessment Demonstration and Clinic for Psoriatic Arthritis
2:25 PM
Dr. Strober / Assessments for health related quality of life for psoriasis and psoriatic arthritis patents
2:40 PM
Dr. Takeshita / Treat to target for psoriasis and PsA
2:55 PM
Dr. Gelfand / Closing
Event Details
  • Date
    Friday, February 16
  • Time
    1:00 PM - 3:00 PM
  • Location
    Room 4
  • CME Credits
    2.00
  • Type
    MOC
Directors/Co-Directors
  • Joel M. Gelfand, MD, MSCE, FAAD
Speakers
  • Bruce Elliot Strober, MD, PhD, FAAD - Handout
  • Joseph Merola, MD, MSc, FAAD
  • Junko Takeshita, MD, PhD, FAAD - Handout
  • Kristina Patrice Callis-Duffin, MD, FAAD - Handout